Renal Cyst Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease
Kidney360 · 29.07.2026
DOI: 10.34067/kid.0000001259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, online erschienen am 29.07.2026. Verfasst von Ross Richard Warren Copping und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Interventional Radiology, University Health Network, Toronto (Canada). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Enlarged cystic kidneys, as measured by total kidney volume (TKV), highly correlate with “mass effect” symptoms and predict early loss of kidney function in autosomal dominant polycystic kidney disease (ADPKD). Sclerotherapy of large kidney cysts can reduce TKV and the associated mass effect. This study assessed if sodium tetradecyl sulfate sclerotherapy provides effective volume reduction in ADPKD and investigated its mechanism of action using porcine bladder models.
Methods
Retrospective review of 567 cysts treated with sodium tetradecyl sulfate in 306 patients between November 2014 and August 2022 was performed. Cysts were treated with single-stage (cyst7cm) sclerotherapy. TKV and treated renal cyst volumes were calculated on MRI to assess response. Renal function and tolvaptan data was collected. To investigate the action of sodium tetradecyl sulfate, porcine bladder models were evaluated using confocal laser endomicroscopy and formalin-fixed hematoxylin and eosin staining, comparing treated and control tissues.
Results
495 cysts had adequate MRI follow-up to determine volume response; 99% of cysts showed volume reduction on first follow-up (mean 162 days), with mean reduction of 197cm 3 (88 ±16%). Larger cysts showed greater volume reduction. Long-term, 80% cysts showed further volume reduction while 18% were stable compared to the first follow-up MRI (mean 1359 days), indicating a sustained response. Mean TKV and mean height-adjusted TKV decreased by 371cm 3 and 224cm 3 respectively at the final follow-up. Serum creatinine increased by 30.5 ±82.6 mg/dL and eGFR decreased by 8.6 ±14.92 mL/min/1.73m 2 at mean follow-up 1460 days. In the porcine bladder models, sodium tetradecyl sulfate showed near complete denudation of the epithelium, superficial inflammatory changes and vascular congestion in the lamina propria without deeper mural injury.
Conclusions
Sodium tetradecyl sulfate sclerotherapy provides effective, sustained long-term volume reduction in treated renal cysts and TKV in ADPKD, and is associated with reduced renal function decline.
Autor:innen und Institutionen
- Division of Interventional Radiology, University Health Network, Toronto (Canada).
- Temerty Faculty of Medicine, University of Toronto, Toronto (Canada).
- Joint Department of Medical Imaging, University of Toronto, Toronto (Canada).
- Department of Nephrology, University Health Network, Toronto (Canada).
- IHU-Strasbourg, Institute of Image guided Surgery, Strasbourg (France).
- Department of General Surgery, University Health Network, Toronto (Canada).
ORCID-Profile: Ross Richard Warren Copping, Paul Li, York Pei, Eran Shlomovitz
Zitieren
APA
Copping, R. R. W., Sabovich, S., Li, P., Miranda Cam, M., Dehkharghanian, T., Pei, Y., Swanstrom, L., & Shlomovitz, E. (2026). Renal Cyst Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease. Kidney360. https://doi.org/10.34067/kid.0000001259
Vancouver
Copping RRW, Sabovich S, Li P, Miranda Cam M, Dehkharghanian T, Pei Y, et al. Renal Cyst Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2026. doi:10.34067/kid.0000001259
BibTeX
@article{Copping2026,
author = {Copping, Ross Richard Warren and Sabovich, Solomon and Li, Paul and Miranda Cam, Mauricio and Dehkharghanian, Taher and Pei, York and Swanstrom, Lee and Shlomovitz, Eran},
title = {Renal Cyst Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease},
journal = {Kidney360},
year = {2026},
doi = {10.34067/kid.0000001259}
}
EUVIMED